Yuhan Corporation Begins Development of mRNA New Drug Platform Technology
Contract for Joint Development with Ewha Womans University and University of Cincinnati
Aiming to Secure Core mRNA and LNP Technologies
[Asia Economy Reporter Lee Gwan-joo] Yuhan Corporation announced on the 7th that it has signed joint research and development contracts with Ewha Womans University and the University of Cincinnati in the United States, respectively, aiming to develop new messenger ribonucleic acid (mRNA) and lipid nanoparticle (LNP) platform technologies.
Yuhan Corporation will take the lead in developing new mRNA platform technology that increases in vivo stability and target protein expression with the research team of Professor Lee Hyuk-jin at Ewha Womans University. Additionally, it plans to develop new LNP platform technology that enhances mRNA delivery efficiency to target tissues with the research team of Professor Lee Ju-yeop at the University of Cincinnati.
Utilizing the platform technologies secured through joint research, Yuhan Corporation plans to proactively advance the commercialization of mRNA therapeutics, including preclinical and clinical development. Initially, it intends to develop immuno-oncology drugs that regulate immune cell functions and establish an R&D strategy that comprehensively considers synergistic effects with other immuno-oncology pipelines currently under development. Furthermore, based on the established technologies, it also plans to expand the application scope of mRNA to therapeutics for various diseases.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Yuhan Corporation’s Research Director Oh Se-woong stated, “The mRNA and LNP research collaboration with Ewha Womans University and the University of Cincinnati is a representative example demonstrating Yuhan Corporation’s commitment to platform technology development, further strengthening and expanding the open innovation with numerous companies conducted so far.” He added, “We plan to derive optimal innovative drug candidates and proceed with preclinical, clinical trials, and global commercialization.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
